Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration was due by March 16 to have decided on the marketing application for Roche and Trimeris's experimental HIV entry inhibitor Fuzeon. (No information was available about the expected approval at press time.) Fuzeon is the first anti-HIV drug to be developed in the entry inhibitor class. The Department of Health and Human Services gave approval in January for OraSure Technologies to more widely distribute its OraQuick Rapid HIV-1 Antibody Test to more than 100,000 sites nationwide, including physicians' offices and HIV counseling centers. The test, which can provide results in about 20 minutes, was approved by the Food and Drug Administration in November. Two four-month studies show that Bio-Technology General Corp.'s anabolic steroid oxandrolone, when combined with exercise and proper nutrition, increases weight and lean body tissue in patients suffering from HIV- or cancer-related wasting. Pharmacia Corp. announced in January that it will allow generic-drug makers to manufacture cheap copies of its HIV nonnucleoside reverse transcriptase inhibitor Rescriptor to sell in 78 developing nations. Two new studies show that Agouron's protease inhibitor Viracept does not increase the risk of birth defects in infants of pregnant women who take the anti-HIV medication and that taking the drug with a moderate-calorie, low-fat meal or a high-calorie, high-fat meal results in blood levels of the drug three to five times higher than achieved when taking it without food. Meanwhile, Roche, the distributor of the drug outside the United States, announced in February that it will slash the cost of Viracept to 'no-profit' prices in sub-Saharan Africa and other poor nations. A year's supply will cost about $800 to $900. Boehringer Ingelheim announced in February the launch of two Phase III clinical trials of its experimental second-generation, nonpeptidic protease inhibitor tipranivir. The trials include 1,500 people at more than 280 sites worldwide. Vertex Pharmaceuticals and GlaxoSmithKline report that a human trial of their once- or twice-daily experimental protease inhibitor GW433908 shows the drug reduced blood-based virus to undetectable levels in 66% of patients previously untreated for HIV disease. A new study shows that Gilead Sciences' experimental nucleoside reverse transcriptase inhibitor Coviracil is effective in suppressing HIV to undetectable levels when taken as part of a once-daily, protease inhibitor'sparing regimen. Auxilium announced on February 4 the launch of Testim, a testosterone gel that can be used in hormone replacement therapy for HIV-positive men with low testosterone levels. Data from a 50-patient study of Tibotec's experimental protease inhibitor TMC114 show that the drug has significant antiviral activity in multiple protease inhibitor'experienced patients currently on failing drug regimens. Roche Pharmaceuticals and Trimeris report that preliminary data from a human trial of their experimental entry inhibitor T-1249 show the compound is effective in suppressing HIV resistant to Fuzeon, the companies' other experimental entry inhibitor. Kucera Pharmaceutical has announced that the company is developing a new synthetic molecule, called KPC-2, that was shown in early tests to prevent HIV replication. The company plans to seek FDA approval to begin clinical trials. Data from a Phase I trial of Indevus (formerly Interneuron) Pharmaceuticals' experimental vaginal microbicide gel PRO 2000 show that the compound is safe and was well tolerated by both sexually active HIV-negative women and HIV-positive, abstinent women. Data from a 96-week clinical trial show that treatment-naive patients taking Gilead Sciences' nucleotide reverse transcriptase inhibitor Viread experience less lipodystrophy and have lower elevations in fasting cholesterol and triglycerides than study subjects taking d4T.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
The Most Amazing HIV Allies & Advocates of 2023
November 03 2023 12:51 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
This OnlyFans Star Is Trying to Raise $100K to Fight HIV
December 26 2023 3:05 PM
The naked Black body takes center stage in this HIV campaign
January 03 2024 1:07 PM
Mr. Gay World wants to make sure you're OK
January 02 2024 4:56 PM
The First Person Cured of AIDS Gets His Due
December 19 2023 1:12 AM
8 dating tips for gay men from a gay psychotherapist
March 21 2024 2:50 PM
HIV Advocate, Journalist Josh Kruger Murdered in His Home
October 06 2023 3:19 PM
Plus: Featured Video
Latest Stories
Find your perfect fit with gender-inclusive fashion from The Pride Store
March 26 2024 2:16 PM
Sexual assault survivor Stephen Hart uses theater to heal
March 25 2024 5:52 PM
Prohibition Wellness & revolutionizing self-care for all
March 22 2024 1:19 PM
Unleash your fiery spirit with The Pride Store’s Aries gift guide
March 21 2024 2:08 PM
Crafting diversity and inclusivity in beauty with Fashion Foundry
March 20 2024 5:27 PM
Vibrant locks rain or shine with The Pride Store's top haircare essentials
March 19 2024 2:13 PM
At risk for syphilis or chlamydia? There’s a PEP for that
March 19 2024 12:04 PM
'Drag Race' star Q shares she's living with HIV
March 18 2024 3:08 PM
Empowering women with Nashelle Jewelry this Women's History Month
March 13 2024 3:05 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
Bloom in your skin with The Pride Store’s skincare essentials
March 12 2024 4:31 PM
Nex Benedict’s tragic death further proves that Oklahoma is not OK
March 12 2024 2:57 PM
Mr. Gay World's Plus cover story: behind the scenes
March 08 2024 4:47 PM
HIV+ man banned from jail work program gets last laugh
March 07 2024 4:14 PM
The Werkroom's artistic rebellion transforms pop culture icons into queer fantasies
March 07 2024 2:23 PM
Get your spring bling on with The Pride Store’s jewelry picks
March 05 2024 4:43 PM
Is this the future of PrEP?
March 01 2024 5:54 PM